{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:59:01Z","timestamp":1790380741429,"version":"4.1.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by extreme immune activation, resulting in pathologic inflammation. The diagnosis includes a spectrum of inherited or acquired defects in cytotoxic lymphocyte function, often with uncontrolled infections. HLH may also arise as the result of persistent antigen stimulation due to autoimmune disease or malignancy. HLH is often described in binary terms as \u201cprimary,\u201d indicating Mendelian inheritance of gene mutations resulting in cytotoxic lymphocyte dysfunction, or \u201csecondary\u201d indicating an acquired reactive disorder. Increasing evidence describes HLH as more complex phenomenon, resulting from specific immune challenges in patients with a susceptible genetic background. Early recognition of HLH and evaluation of potential causes is critically important, as survival generally requires urgent treatment with immune suppression and resolution of the activating antigen. However, the diagnosis of HLH is challenged by the myriad of pathways that lead to pathologic inflammation and the clinical overlap with other conditions. Further improvements in therapy will require prospective trials to define optimal strategies for each patient based on the individual paths that lead to pathologic inflammation.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.177","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"177-182","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":138,"title":["Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis"],"prefix":"10.1182","volume":"2015","author":[{"given":"Carl E.","family":"Allen","sequence":"first","affiliation":[{"name":"Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX; and"},{"name":"Department of Pediatrics, Graduate Program in Translational Biology and Molecular Medicine, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"McClain","sequence":"additional","affiliation":[{"name":"Texas Children's Cancer Center, Texas Children's Hospital, Houston, TX; and"},{"name":"Department of Pediatrics, Graduate Program in Translational Biology and Molecular Medicine, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704175818400_B1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00443367","article-title":"Familial hemophagocytic lymphohistiocytosis","volume":"140","author":"Janka","year":"1983","journal-title":"Eur J Pediatr"},{"issue":"136","key":"2019111704175818400_B2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/adc.27.136.519","article-title":"Familial haemophagocytic reticulosis","volume":"27","author":"Farquhar","year":"1952","journal-title":"Arch Dis Child"},{"key":"2019111704175818400_B3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2019111704175818400_B4","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"2019111704175818400_B5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"2019111704175818400_B6","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jpeds.2013.06.053","article-title":"Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment","volume":"163","author":"Chandrakasan","year":"2013","journal-title":"J Pediatr"},{"key":"2019111704175818400_B7","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"key":"2019111704175818400_B8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/302194","article-title":"Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity","volume":"64","author":"Dufourcq-Lagelouse","year":"1999","journal-title":"Am J Hum Genet"},{"key":"2019111704175818400_B9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.blre.2014.03.002","article-title":"Hemophagocytic syndromes: an update","volume":"28","author":"Janka","year":"2014","journal-title":"Blood Rev"},{"key":"2019111704175818400_B10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/humu.20274","article-title":"Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A","volume":"27","author":"Zur","year":"2006","journal-title":"Hum Mutat"},{"key":"2019111704175818400_B11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jmg.2007.052670","article-title":"Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations","volume":"45","author":"Trizzino","year":"2008","journal-title":"J Med Genet"},{"key":"2019111704175818400_B12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jmg.2010.085456","article-title":"Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3","volume":"48","author":"Sieni","year":"2011","journal-title":"J Med Genet"},{"key":"2019111704175818400_B13","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1182\/blood-2011-12-398958","article-title":"Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5)","volume":"119","author":"Pagel","year":"2012","journal-title":"Blood"},{"key":"2019111704175818400_B14","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1182\/blood-2011-07-370148","article-title":"Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"2019111704175818400_B15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1182\/blood-2014-05-573105","article-title":"Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis","volume":"124","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"2019111704175818400_B16","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3201\/eid1008.030928","article-title":"Crimean-Congo hemorrhagic fever in Turkey","volume":"10","author":"Karti","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"2019111704175818400_B17","first-page":"4","article-title":"Ebola virus disease has features of hemophagocytic lymphohistiocytosis syndrome","volume":"2","author":"van der Ven","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"2019111704175818400_B18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3201\/eid0606.000608","article-title":"Hemophagocytic syndromes and infection","volume":"6","author":"Fisman","year":"2000","journal-title":"Emerg Infect Dis"},{"key":"2019111704175818400_B19","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/blood-2010-11-316745","article-title":"Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States","volume":"117","author":"Cohen","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111704175818400_B20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10875-015-0168-y","article-title":"Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18\u20132) and PRF1 (perforin 1)","volume":"35","author":"Cohen","year":"2015","journal-title":"J Clin Immunol"},{"key":"2019111704175818400_B21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.13102","article-title":"Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide","volume":"168","author":"Arca","year":"2015","journal-title":"Br J Haematol"},{"key":"2019111704175818400_B22","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2001.19.10.2665","article-title":"Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis","volume":"19","author":"Imashuku","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111704175818400_B23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.13462","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents","volume":"170","author":"Lehmberg","year":"2015","journal-title":"Br J Haematol"},{"key":"2019111704175818400_B24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/pbc.20950","article-title":"Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis","volume":"50","author":"O'Brien","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2019111704175818400_B25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00277-011-1239-7","article-title":"Possible prediction of underlying lymphoma by high sIL-2R\/ferritin ratio in hemophagocytic syndrome","volume":"91","author":"Tabata","year":"2012","journal-title":"Ann Hematol"},{"key":"2019111704175818400_B26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3899\/jrheum.100996","article-title":"An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"38","author":"Davi","year":"2011","journal-title":"J Rheumatol"},{"key":"2019111704175818400_B27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.bor.0000381996.69261.71","article-title":"Macrophage activation syndrome: advances towards understanding pathogenesis","volume":"22","author":"Grom","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"2019111704175818400_B28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11926-014-0439-2","article-title":"Genetic defects in cytolysis in macrophage activation syndrome","volume":"16","author":"Zhang","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"2019111704175818400_B29","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/art.38793","article-title":"Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis","volume":"66","author":"Kaufman","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2019111704175818400_B30","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.22416","article-title":"The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis","volume":"56","author":"Bleesing","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"2019111704175818400_B31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/BOR.0b013e32834dd37e","article-title":"Not all hemophagocytes are created equally: appreciating the heterogeneity of the hemophagocytic syndromes","volume":"24","author":"Canna","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2019111704175818400_B32","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/mt.2014.48","article-title":"Systemic inflammatory response syndrome after administration of unmodified T lymphocytes","volume":"22","author":"Papadopoulou","year":"2014","journal-title":"Mol Ther"},{"key":"2019111704175818400_B33","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"2019111704175818400_B34","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111704175818400_B35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"2019111704175818400_B36","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fimmu.2013.00448","article-title":"Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice","volume":"4","author":"Jessen","year":"2013","journal-title":"Front Immunol"},{"key":"2019111704175818400_B37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"2019111704175818400_B38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-2141.2008.07298.x","article-title":"Early diagnostic and prognostic significance of a specific Th1\/Th2 cytokine pattern in children with haemophagocytic syndrome","volume":"143","author":"Tang","year":"2008","journal-title":"Br J Haematol"},{"key":"2019111704175818400_B39","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1182\/blood-2013-04-495309","article-title":"Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells","volume":"121","author":"Terrell","year":"2013","journal-title":"Blood"},{"key":"2019111704175818400_B40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.1302282","article-title":"Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis","volume":"192","author":"Johnson","year":"2014","journal-title":"J Immunol"},{"key":"2019111704175818400_B41","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J Clin Invest"},{"key":"2019111704175818400_B42","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/art.22981","article-title":"Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome","volume":"56","author":"Fall","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2019111704175818400_B43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/PCC.0b013e3181a1ae08","article-title":"Secondary hemophagocytic lymphohistiocytosis and severe sepsis\/ systemic inflammatory response syndrome\/multiorgan dysfunction syndrome\/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation","volume":"10","author":"Castillo","year":"2009","journal-title":"Pediatr Crit Care Med"},{"key":"2019111704175818400_B44","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1182\/blood-2011-07-369090","article-title":"Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D","volume":"118","author":"Meeths","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111704175818400_B45","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/pbc.25308","article-title":"Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden","volume":"62","author":"Meeths","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2019111704175818400_B46","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.21423","article-title":"Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis","volume":"50","author":"Allen","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2019111704175818400_B47","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/pbc.25058","article-title":"Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis","volume":"61","author":"Lehmberg","year":"2014","journal-title":"Pediatr Blood Cancer"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/177\/1250345\/bep00115000177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/177\/1250345\/bep00115000177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:18:18Z","timestamp":1573982298000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/177\/20676\/Pathophysiology-and-epidemiology-of-hemophagocytic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.177","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}